NovoCure (NASDAQ: NVCR) CMO reports tax sale and new stock awards

Rhea-AI Filing Summary

NovoCure Ltd chief medical and innovation officer Uri Weinberg reported several equity transactions. He sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding tied to restricted stock unit vesting, a sale mandated by the company’s equity plan. Following this sale, he held 267,190 ordinary shares. Weinberg also received 50,125 ordinary shares as a grant of restricted share units and 73,340 stock options, both at a grant price of $0.00. The restricted share units are scheduled to vest in three equal parts on the first, second, and third anniversaries of the grant date, while the stock options vest in four equal parts on the first through fourth anniversaries, each subject to his continued employment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weinberg Uri

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chf Medical and Innovation Ofr

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		A		50,125	A	$0.00	273,602	D
Ordinary Shares	03/04/2026		S		6,412(2)	D	$13.3054(3)	267,190	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.3	03/03/2026		A		73,340		(4)	03/03/2036	Ordinary Shares	73,340	$0.00	73,340	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

3. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.

4. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Remarks:

	Steven Robbins, as attorney in fact for Weinberg, Uri	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NovoCure (NVCR) executive Uri Weinberg report?

Uri Weinberg reported a mandatory sale of 6,412 ordinary shares and the receipt of 50,125 restricted share units and 73,340 stock options, all held directly. These transactions reflect equity compensation grants and related tax withholding activity disclosed in the Form 4.

How many NovoCure (NVCR) shares did Uri Weinberg sell, and at what price?

Uri Weinberg sold 6,412 ordinary shares at a weighted average price of $13.3054 per share. The transaction was executed in multiple trades between $13.21 and $13.445, and the sale was used to satisfy tax withholding obligations from restricted stock unit vesting.

Were Uri Weinberg’s NovoCure (NVCR) share sales discretionary trades?

The 6,412-share sale was not discretionary; it was mandated by NovoCure’s award agreement as a sell-to-cover transaction. The proceeds funded tax withholding obligations arising from restricted stock unit vesting under the company’s equity incentive plans.

What new equity awards did Uri Weinberg receive from NovoCure (NVCR)?

Uri Weinberg received 50,125 ordinary shares in the form of restricted share units and 73,340 stock options. The restricted share units vest in three equal annual installments, and the options vest in four equal annual installments, each subject to his continued employment with the company.

How many NovoCure (NVCR) shares does Uri Weinberg hold after these transactions?

After the 6,412-share tax-related sale, Uri Weinberg directly held 267,190 ordinary shares. In addition, he held 73,340 stock options from a new grant and 50,125 restricted share units scheduled to vest over a multi-year period, all reported in the Form 4.